Here's a great review of the current situation.
By getting in on the market sooner than expected, Apotex now has 180 days to sell its generic version of Plavix without competition from another generic unless BMS and Sanofi win an injunction to halt sales.
We should hear about that next week.
Even if the decision goes against Apotex, their negotiated contract with BMS and Sanofi limits any compensation; they will still make money!
CEO Barry Sherman figures sales could reach $2-billion during the 180 days, making it the most successful generic launch ever.
Since Aug. 8, Apotex has shipped more than 300 million pills.
The generic drug's market share accounts for more than 60 per cent of total Plavix prescriptions and 74 per cent of new prescriptions.
Mr Sherman is in line for PharmaGossip's Person of the Year Award!
No comments:
Post a Comment